These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 16940065

  • 1. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.
    Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, Csajka C.
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3801-8. PubMed ID: 16940065
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.
    Csajka C, Marzolini C, Fattinger K, Décosterd LA, Telenti A, Biollaz J, Buclin T.
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3226-32. PubMed ID: 15328077
    [Abstract] [Full Text] [Related]

  • 3. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
    Fabbiani M, Di Giambenedetto S, Ragazzoni E, Colafigli M, Prosperi M, Cauda R, Navarra P, De Luca A.
    HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407
    [Abstract] [Full Text] [Related]

  • 4. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S, Buclin T, Franc C, Guignard N, Khonkarly M, Tarr PE, Rochat B, Biollaz J, Telenti A, Decosterd LA, Cavassini M.
    Antivir Ther; 2006 May; 11(1):53-62. PubMed ID: 16518960
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
    von Hentig N, Müller A, Rottmann C, Wolf T, Lutz T, Klauke S, Kurowski M, Oertel B, Dauer B, Harder S, Staszewski S.
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
    [Abstract] [Full Text] [Related]

  • 6. Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.
    Feldt T, Oette M, Kroidl A, Göbels K, Leidel R, Sagir A, Kuschak D, Häussinger D.
    Eur J Med Res; 2005 Jan 28; 10(1):7-10. PubMed ID: 15737947
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
    Bertz RJ, Persson A, Chung E, Zhu L, Zhang J, McGrath D, Grasela D.
    Pharmacotherapy; 2013 Mar 28; 33(3):284-94. PubMed ID: 23456732
    [Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E, Santos Buelga D, Cabrera Figueroa S, López Galera RM, Ribera Pascuet E, Domínguez-Gil Hurlé A, García Sánchez MJ.
    Ther Drug Monit; 2011 Oct 28; 33(5):573-82. PubMed ID: 21912331
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.
    Solas C, Gagnieu MC, Ravaux I, Drogoul MP, Lafeuillade A, Mokhtari S, Lacarelle B, Simon N.
    Ther Drug Monit; 2008 Dec 28; 30(6):670-3. PubMed ID: 18806695
    [Abstract] [Full Text] [Related]

  • 12. Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
    Schipani A, Dickinson L, Boffito M, Austin R, Owen A, Back D, Khoo S, Davies G.
    J Acquir Immune Defic Syndr; 2013 Jan 01; 62(1):60-6. PubMed ID: 23011396
    [Abstract] [Full Text] [Related]

  • 13. Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.
    Hong Y, Kowalski KG, Zhang J, Zhu L, Horga M, Bertz R, Pfister M, Roy A.
    Antimicrob Agents Chemother; 2011 Dec 01; 55(12):5746-52. PubMed ID: 21930880
    [Abstract] [Full Text] [Related]

  • 14. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
    Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Conti F, Clementi E.
    Ther Drug Monit; 2010 Dec 01; 32(6):782-6. PubMed ID: 20926993
    [Abstract] [Full Text] [Related]

  • 15. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
    Gutierrez-Valencia A, Ruiz-Valderas R, Torres-Cornejo A, Viciana P, Espinosa N, Castillo-Ferrando JR, Lopez-Cortes LF.
    Clin Infect Dis; 2014 Jan 01; 58(2):268-73. PubMed ID: 24145880
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
    Gianotti N, Seminari E, Guffanti M, Boeri E, Villani P, Regazzi M, Bigoloni A, Schira G, Tiberi S, Fusetti G, Lazzarin A, Castagna A.
    New Microbiol; 2005 Apr 01; 28(2):119-25. PubMed ID: 16035256
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
    Brendel K, Legrand M, Taburet AM, Baron G, Goujard C, Mentré F, Cophar 1-ANRS 102 Trial Group.
    Fundam Clin Pharmacol; 2005 Jun 01; 19(3):373-83. PubMed ID: 15910662
    [Abstract] [Full Text] [Related]

  • 19. Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients.
    Crutchley RD, Ma Q, Sulaiman A, Hochreitter J, Morse GD.
    J Pharm Pract; 2011 Apr 01; 24(2):216-22. PubMed ID: 21712217
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.